Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,551 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Ulcerative Clear all

Conditions: Ulcerative Colitis
Interventions: Rosnilimab, Placebo; Drug
Lead sponsor: AnaptysBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 25
States / cities: Phoenix, Arizona • Garden Grove, California • Lancaster, California + 20 more

Conditions: Chronic Ulcer of Lower Extremity
Interventions: PalinGen Flow Amniotic Tissue Allograft; Biological
Lead sponsor: Amnio Technology, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Carmichael, California • Castro Valley, California • Fresno, California + 4 more

Conditions: Ulcerative Colitis
Interventions: BT-11 (440 mg), BT-11 (880 mg), Placebo; Drug
Lead sponsor: NImmune Biopharma; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 9
States / cities: Los Angeles, California • Ventura, California • Walnut Creek, California + 6 more

Conditions: Achlorhydria, Gastrinoma, Zollinger Ellison Syndrome
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1989 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Foot Ulcers
Interventions: Omeza collagen matrix, Omeza lidocaine lavage, Omeza skin protectant; Combination Product
Lead sponsor: Omeza, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Toledo, Ohio

Conditions: Diabetic Foot Infections
Interventions: 18F-FDG PET/CT; Diagnostic Test
Lead sponsor: Jewish General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Venous Leg Ulcers
Interventions: Bacteriophage, WPP-201 Bacteriophage, Bacteriophages; Drug
Lead sponsor: Southwest Regional Wound Care Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Diabetic Foot Ulcer
Interventions: Dermagraft(R), Conventional care; Device · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 1997
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetic Foot Ulcer
Interventions: Weekly application of EpiFix plus standard of care, Biweekly application of EpiFix plus standard of care; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Roanoke, Virginia • Salem, Virginia

Conditions: Ulcerative Colitis
Interventions: Asacol (mesalamine); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Neuropathic Diabetic Foot Ulcer
Interventions: MatriStem® [Urinary Bladder Matrix (UBM)], Mepilex® [Silicone foam dressing]; Device
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 85 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Aortic Dissection, Intramural Hematoma, Penetrating Ulcer, Pseudoaneurysm
Interventions: Endovascular repair with Valiant PS-IDE Stent Graft; Device
Lead sponsor: Rodney A. White, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2033
U.S. locations: 3
States / cities: Long Beach, California • Los Angeles, California • Torrance, California

Conditions: Proctitis, Proctosigmoiditis
Interventions: Budesonide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 63
States / cities: Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more

Conditions: Ulcerative Colitis
Interventions: Mesalazine, IV Corticosteroid, Oral Corticosteroids, Additional Therapies, Colectomy; Drug · Other · Procedure
Lead sponsor: Connecticut Children's Medical Center; Other
Eligibility: 4 Years to 17 Years
Enrollment: 431 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 26
States / cities: Los Angeles, California • San Francisco, California • Hartford, Connecticut + 22 more

Conditions: Diabetes, Diabetic Foot, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Interventions: Cytal Wound Matrix 1-Layer, Standard of Care (SOC); Device · Other
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 21 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Fresno, California • New Orleans, Louisiana • Hyattsville, Maryland

Conditions: Pressure Ulcers
Interventions: Placebo, Thymosin Beta 4; Drug
Lead sponsor: RegeneRx Biopharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 12
States / cities: Montgomery, Alabama • Beverly Hills, California • Long Beach, California + 9 more

Conditions: Pressure Ulcer
Interventions: dHACM; Other
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 16 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease
Interventions: Not listed
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 1 Year to 18 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 1 more

Conditions: Diabetic Foot Ulcer (DFU)
Interventions: OneStep Foot Scanner; Device
Lead sponsor: Bluedrop Medical Limited; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: North Port, Florida • Monroeville, Pennsylvania

Conditions: Ulcerative Colitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis
Interventions: Coral FRS test; Diagnostic Test
Lead sponsor: Coral Genomics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Transtibial Amputation
Interventions: Walk, Yuga post, E-SWEAT Sensor; Procedure · Device
Lead sponsor: North Carolina State University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Raleigh, North Carolina

Conditions: Diabetic Foot Ulcer
Interventions: InnovaMatrix AC porcine placental ECM therapy; Device
Lead sponsor: ConvaTec Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 5
States / cities: North Port, Florida • Buffalo, New York • Monroeville, Pennsylvania + 2 more

Conditions: Inflammatory Bowel Disease, Ulcerative Colitis
Interventions: Balsalazide Disodium; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 95
States / cities: Birmingham, Alabama • Tempe, Arizona • Fayetteville, Arkansas + 82 more

Conditions: Ulcerative Colitis
Interventions: BT051 200 mg, BT051 800 mg, BT051 3200 mg, Matching Placebo; Drug
Lead sponsor: Adiso Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Rialto, California • Kissimmee, Florida

Search by objective public record fields.

A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)

Safety and Preliminary Efficacy of PalinGen Flow Amniotic Tissue Allograft in Chronic Ulcers of the Lower Extremities

Efficacy and Safety of Oral BT-11 in Ulcerative Colitis

Evaluating Patients With Abnormal Levels of Gastric Acid

Omeza Products in Combination With Standard of Care for the Treatment of Diabetic Foot Ulcers

18F-FDG PET/CT for Diagnosis of Diabetic Foot Osteomyelitis

A Prospective, Randomized, Double-Blind Controlled Study of WPP-201 for the Safety and Efficacy of Treatment of Venous Leg Ulcers

Dermagraft(R) for the Treatment of Patients With Diabetic Foot Ulcers

Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers

Asacol Dosing Study for Active Ulcerative Colitis

A Longitudinal Study to Evaluate an Extracellular Matrix (MatriStem®) for the Treatment of Diabetic Foot Ulcers

Feasibility of Endovascular Repair Of Ascending Aortic Pathologies

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

Predicting Response to Standardized Pediatric Colitis Therapy

Diabetic Foot Ulcer Study Comparing Cytal Wound Matrix 1-Layer to Standard of Care

Study of Thymosin Beta 4 in Patients With Pressure Ulcers

Case Series of Weekly Applications of dHACM in Treatment of Pressure Ulcers

COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)

Remote Temperature and Visual Monitoring To Help Manage Diabetic Foot Ulcers

Predicting Medication Response for Autoimmune Disease

Epidermal Sensors for Wireless and Enhanced Amputee Skin Tracking (E-SWEAT) Part 1

Sterilised, Porcine Placental Tissue in the Treatment of Chronic Diabetic Foot Ulcers

Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study

An Investigation of Oral BT051 in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)